THOUSAND OAKS, Calif.,
Nov. 10, 2016 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) will host a webcast investor meeting at the American
Heart Association (AHA) Scientific Sessions 2016 on Tuesday, Nov. 15, 2016, at 7 p.m. CT. Sean E.
Harper, M.D., executive vice president of Research and
Development at Amgen, along with members of Amgen's clinical
development team and clinical investigators, will participate at
the investor meeting to discuss Amgen's cardiovascular program and
data presented at AHA, including the Repatha coronary imaging study
(GLAGOV) Phase 3 results.
Live audio of the investor meeting will be simultaneously
broadcast over the internet and will be available to members of the
news media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences, can be found on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Kristen Neese, 805-313-8267
(media)
Arvind Sood, 805-447-1060
(investors)
Logo -
http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessions-2016-300360954.html
SOURCE Amgen